Kintara Therapeutics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Kintara Therapeutics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	23.2%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Kintara soars 66% on pausing breast cancer study, to use cash for brain cancer trial

Oct 19

Kintara Therapeutics GAAP EPS of -$0.52

Sep 27

Kintara Therapeutics rallies after $20M stock purchase deal with Lincoln Park Capital Fund

Aug 03

Kintara Therapeutics reports VAL-083 interim data for the treatment of glioblastoma multiforme

Nov 19

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kintara Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:KTRA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	N/A	-11	-7	-7	N/A
9/30/2023	N/A	-13	-7	-7	N/A
6/30/2023	N/A	-15	-12	-12	N/A
3/31/2023	N/A	-17	-16	-15	N/A
12/31/2022	N/A	-19	-19	-19	N/A
9/30/2022	N/A	-22	-22	-22	N/A
6/30/2022	N/A	-25	-20	-20	N/A
3/31/2022	N/A	-26	-20	-20	N/A
12/31/2021	N/A	-28	-20	-19	N/A
9/30/2021	N/A	-27	-20	-20	N/A
6/30/2021	N/A	-42	-19	-19	N/A
3/31/2021	N/A	-39	-17	-17	N/A
12/31/2020	N/A	-34	-13	-13	N/A
9/30/2020	N/A	-30	-10	-10	N/A
6/30/2020	N/A	-9	-8	-8	N/A
3/31/2020	N/A	-8	-7	-7	N/A
12/31/2019	N/A	-8	-7	-7	N/A
9/30/2019	N/A	-8	-7	-7	N/A
6/30/2019	N/A	-8	-6	-6	N/A
3/31/2019	N/A	-8	-7	-7	N/A
12/31/2018	N/A	-9	-8	-8	N/A
9/30/2018	N/A	-11	-10	-10	N/A
6/30/2018	N/A	-11	-10	-10	N/A
3/31/2018	N/A	-12	-11	-11	N/A
12/31/2017	N/A	-11	-9	-9	N/A
9/30/2017	N/A	-9	N/A	-9	N/A
6/30/2017	N/A	-9	N/A	-8	N/A
3/31/2017	N/A	-10	N/A	-6	N/A
12/31/2016	N/A	-9	N/A	-6	N/A
9/30/2016	N/A	-10	N/A	-5	N/A
6/30/2016	N/A	-9	N/A	-5	N/A
3/31/2016	N/A	-6	N/A	-4	N/A
12/31/2015	N/A	-6	N/A	-4	N/A
9/30/2015	N/A	-4	N/A	-4	N/A
6/30/2015	N/A	-4	N/A	-4	N/A
3/31/2015	N/A	-1	N/A	-4	N/A
12/31/2014	N/A	-2	N/A	-4	N/A
9/30/2014	N/A	-2	N/A	-4	N/A
6/30/2014	N/A	6	N/A	-4	N/A
3/31/2014	N/A	-4	N/A	-4	N/A
12/31/2013	N/A	-8	N/A	-6	N/A
9/30/2013	N/A	-8	N/A	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if KTRA's forecast earnings growth is above the savings rate (2.4%).

Earnings vs Market: Insufficient data to determine if KTRA's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if KTRA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if KTRA's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if KTRA's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if KTRA's Return on Equity is forecast to be high in 3 years time

Kintara Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

No longer forecast to breakeven

Price target decreased to US$3.17

Price target decreased to US$4.00

Price target decreased to US$5.56

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Recent updates

Insufficient new directors

TuHURA Biosciences, Inc. entered into a definitive agreement to acquire Kintara Therapeutics, Inc. (NasdaqCM:KTRA) in a reverse merger transaction.

Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab

Kintara Therapeutics, Inc. has withdrawn its Follow-on Equity Offering.

Kintara Therapeutics, Inc. Announces Initiation of Rem-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer

New major risk - Revenue and earnings growth

Kintara Therapeutics Receives Non-Compliance Notice from Nasdaq

Nasdaq Grants Extension to Kintara Therapeutics to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement

New major risk - Shareholder dilution

Kintara Therapeutics, Inc. Announces Executive Changes

New major risk - Negative shareholders equity

New major risk - Share price stability

Kintara Therapeutics Receives Non-Compliance Notice From Nasdaq

Kintara Therapeutics, Inc. Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting

No longer forecast to breakeven

Kintara Therapeutics Receives Orphan Drug Designation for VAL-083 for Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)

Kintara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Kintara Therapeutics Grants Fast Track Designation from FDA for Rem-001 for Cutaneous Metastatic Breast Cancer

Kintara Therapeutics, Inc. Pauses REM-001 Program to Conserve Funds to Support Val-083 International Registrational Study

Kintara soars 66% on pausing breast cancer study, to use cash for brain cancer trial

Kintara Therapeutics GAAP EPS of -$0.52

Kintara Therapeutics Receives Study May Proceed Letter from the FDA for REM-001 for Cutaneous Metastatic Breast Cancer

Kintara Therapeutics, Inc. announced that it expects to receive $20 million in funding from Lincoln Park Capital, LLC

Kintara Therapeutics rallies after $20M stock purchase deal with Lincoln Park Capital Fund

Kintara Therapeutics Grants Fast Track Designation from the FDA for VAL-083 for Newly-Diagnosed Glioblastoma

Kintara Receives 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement

Kintara Therapeutics, Inc. Announces First European Site Activation in Switzerland in GCAR Phase 2/3 Clinical Trial for Glioblastoma

Saiid Zarrabian to Step Down from His Role as Head of Strategic Partnerships and as A Member of the Board of Kintara Therapeutics

Kintara Therapeutics, Inc., Annual General Meeting, Jun 21, 2022

Price target decreased to US$3.17

High number of new and inexperienced directors

Kintara Therapeutics (NASDAQ:KTRA) Will Have To Spend Its Cash Wisely

Kintara Therapeutics, Inc. Announces Resignation of Keith Murphy from the Board of Directors

Kintara Therapeutics, Inc. Announces Issuance of New US Patent Related to Val-083 and MGMT Resistance

Price target decreased to US$4.00

GCAR Screens Over 1,000 Patients for GBM

Kintara Therapeutics Receives A Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Kintara Announces First International Site Activation in GCAR Phase 2/3 Clinical Trial for Glioblastoma

Price target decreased to US$5.56

Kintara Therapeutics, Inc. Reports Topline Results from Phase 2 Clinical Study of Val-083 as Adjuvant Therapy for Newly-Diagnosed GBM Patients

Kintara Therapeutics Provides Positive Site Activation Update on Gcar Phase 2/3 Clinical Trial for Glioblastoma

Kintara Reports Topline Results From Phase 2 Clinical Trial of VAL-083 for Recurrent GBM

Kintara Therapeutics, Inc. Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors

Kintara Therapeutics Provides Positive Site Activation Update on Gcar Phase 2/3 Clinical Trial for Glioblastoma

Forecast to breakeven in 2024

Kintara Therapeutics shares rise on mid-stage glioblastoma trial update

Forecast to breakeven in 2024

Kintara Therapeutics, Inc. Appoints Mario Lacouture to the REM-001 Scientific Advisory Board

Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Recurrent GBM

New 90-day high: US$2.19

New 90-day high: US$1.87

Kintara Announces Initiation of Patient Recruitment for VAL-083's Study Arm in the GBM AGILE Trial

Kintara initiates recruitment for VAL-083's study arm in the GBM AGILE trial

Global Coalition for Adaptive Research, Kazia, and Kintara Announce Commencement of Kazia’s Paxalisib and Kintara’s VAL-083 in GBM AGILE Trial

Kintara Therapeutics, Inc. Announces Interim Data on Its Two Phase 2 Trials of VAL-083

Kintara Therapeutics reports VAL-083 interim data for the treatment of glioblastoma multiforme

New 90-day high: US$1.72

DelMar Pharmaceuticals, Inc. (NasdaqCM:DMPI) entered into a definitive merger agreement to acquire Adgero Biopharmaceuticals Holdings, Inc.

New 90-day high - US$1.50

Kintara Therapeutics, Inc. announced that it has received $25.028 million in funding

Kintara Therapeutics, Inc. Regains Compliance with NASDAQ Minimum Bid Price Requirement

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies